22nd Century Group (NYSE: XXII) is a plant biotechnology company that uses genetic engineering and plant breeding technology to decrease or increase the level of nicotine and other nicotinic alkaloids in tobacco plants. The company is also developing a prescription smoking cessation aid; modified risk cigarettes with approximately 95% less nicotine than conventional tobacco cigarettes; cigarettes with low amounts of tar per milligram of nicotine; and, through a collaboration with Anandia Laboratories, has exclusive U.S. rights to genes required to produce cannabinoids. Technology licensed from Anandia allows for development of cannabis strains that increase or decrease the content of cannabinoids. For more information, visit the company’s website at www.xxiicentury.com